ライフサイエンスコーパス: serum hepatitis

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 association between TDAV infection and acute serum hepatitis.

2 tiviral activity as evidenced by the loss of serum hepatitis B e antigen and hepatitis B virus (HBV)

3 irologic response (defined by the absence of serum hepatitis B e antigen and serum HBV DNA) at week 5

4 BV) DNA in serum and 45 (87%) had detectable serum hepatitis B e antigen before treatment.

5 trols, chronic HBV infection was assessed by serum hepatitis B surface antigen (HBsAg) and AFB1 expos

6 ion recipients of livers from donors without serum hepatitis B surface antigen (HBsAg) but with antib

7 This study investigated the role of serum hepatitis B surface antigen (HBsAg) levels and est

8 V) preS/S gene variability has any impact on serum hepatitis B surface antigen (HBsAg) levels and to

9 The profile and clinical significance of serum hepatitis B surface antigen (HBsAg) levels during

10 participants, 603,585 had baseline data for serum hepatitis B surface antigen (HBsAg) status and wer

11 The patient is clinically normal, serum hepatitis B surface antigen negative at 10 months

12 on included the following: illicit drug use, serum hepatitis B surface antigen positive, grade 1 ence

13 smoking, elevated alanine aminotransferase, serum hepatitis B surface antigen, anti-hepatitis C viru

14 ex, smoking, serum alanine aminotransferase, serum hepatitis B surface antigen, anti-hepatitis C viru

15 of the post-LT cohort achieved undetectable serum hepatitis B virus (HBV) DNA (Roche Amplicor Monito

16 corresponds to the degree of suppression of serum hepatitis B virus (HBV) DNA achieved with therapy.

17 Hepatitis B e antigen (HBeAg) status and serum hepatitis B virus (HBV) DNA levels are major facto

18 ansferase levels (Group I) maintained higher serum hepatitis B virus (HBV) DNA levels but significant

19 ed alanine transaminase (ALT) levels and low serum hepatitis B virus (HBV) DNA predict a higher likel

20 percent, P=0.003), sustained suppression of serum hepatitis B virus (HBV) DNA to undetectable levels

21 Serum hepatitis B virus (HBV) DNA was detectable using b

22 Serum hepatitis B virus (HBV) DNA was detected by soluti

23 243; lamivudine, n = 164) were assessed for serum hepatitis B virus (HBV) DNA, alanine aminotransfer

24 e replication and drug resistance of patient serum hepatitis B virus (HBV) populations can contribute

25 The serum hepatitis B virus (HBV) surface antigen (HBsAg) le

26 ed for HBsAg, hepatitis B e antigen (HBeAg), serum hepatitis B virus (HBV)-DNA levels, and anti-hepat

27 ears achieved the primary efficacy endpoint (serum hepatitis B virus [HBV] DNA <1,000 copies/mL and n

28 e monitoring of CHB patients with detectable serum hepatitis B virus DNA in European tertiary referra

29 rapy, compared with conventional measures of serum hepatitis B virus DNA.

30 of 10 g/d has been associated with increased serum hepatitis C viral RNA and aminotransferase levels,

31 Efficacy was assessed by measurements of serum hepatitis C virus (HCV) RNA and serum aminotransfe

32 saminase (ALT) concentration and decrease in serum hepatitis C virus (HCV) RNA concentration below th

33 and virological responses (percent negative serum hepatitis C virus [HCV] RNA) after treatment.

34 breakthrough/relapse patients (undetectable serum hepatitis C virus RNA after 24 weeks of peginterfe

35 irologic response (undetectable [<125 IU/mL] serum hepatitis C virus RNA at 24-week follow-up).

36 genotype 1 hepatitis C virus infection with serum hepatitis C virus RNA concentrations of at least 5

37 vel of serum aminotransferases, the level of serum hepatitis C virus RNA, and histologic necroinflamm

38 on the achievement of sustained clearance of serum hepatitis C virus RNA, which is influenced, in tur

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。